These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37860956)

  • 1. A multistate platform model for time-to-event endpoints in oncology clinical trials.
    Lin CW; Nagase M; Doshi S; Dutta S
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):154-167. PubMed ID: 37860956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model.
    Nagase M; Doshi S; Dutta S; Lin CW
    J Pharmacokinet Pharmacodyn; 2022 Aug; 49(4):455-469. PubMed ID: 35870059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer.
    Liu H; Milenković-Grišić AM; Krishnan SM; Jönsson S; Friberg LE; Girard P; Venkatakrishnan K; Vugmeyster Y; Khandelwal A; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1738-1750. PubMed ID: 37165943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical considerations in clinical trial design with event-free survival as the primary efficacy endpoint.
    Xu T; Zhang Y; Goldwasser M; Zhang V
    Pharm Stat; 2021 Jul; 20(4):721-736. PubMed ID: 33594827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.
    Trippa L; Wen PY; Parmigiani G; Berry DA; Alexander BM
    Neuro Oncol; 2015 Aug; 17(8):1106-13. PubMed ID: 25568226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
    Nomura S; Hirakawa A; Hamada C
    J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
    Etekal T; Koehn K; Sborov DW; McClune B; Prasad V; Haslam A; Berger K; Booth C; Al Hadidi S; Abdallah AO; Goodman A; Mohyuddin GR
    Br J Haematol; 2023 Mar; 200(5):587-594. PubMed ID: 36495317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multistate model for early decision-making in oncology.
    Beyer U; Dejardin D; Meller M; Rufibach K; Burger HU
    Biom J; 2020 May; 62(3):550-567. PubMed ID: 31310368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
    Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
    J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
    [No Abstract]   [Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
    Mushti SL; Mulkey F; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
    [No Abstract]   [Full Text] [Related]  

  • 15. The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
    Woodford RG; Zhou DD; Kok PS; Lord SJ; Friedlander M; Marschner IC; Simes RJ; Lee CK
    Cancer; 2022 Apr; 128(7):1449-1457. PubMed ID: 34985773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ; Kim KW
    Korean J Radiol; 2020 Apr; 21(4):471-482. PubMed ID: 32193895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
    Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
    Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data.
    Tan K; Bryan J; Segal B; Bellomo L; Nussbaum N; Tucker M; Torres AZ; Bennette C; Capra W; Curtis M; Miksad RA
    Clin Pharmacol Ther; 2022 Jan; 111(1):168-178. PubMed ID: 34197637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of surrogate endpoints for predicting real-world survival across five cancer types.
    Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
    Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients.
    Lim HS; Sun W; Parivar K; Wang D
    AAPS J; 2019 Jan; 21(2):22. PubMed ID: 30701431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.